|Videos|August 1, 2020

ASRS 2020: Diabetic retinopathy progression in anti-VEGF versus FA implant

Caesar Luo, MD, shares the take-away points from his ASRS presentation, and how the topics from his talk may be applied day to day in retinal practice.

Caesar Luo, MD, speaks with Modern Retina®/Ophthalmology Times®' Sheryl Stevenson on the take-away points from his presentation on diabetic retinopathy progression in anti-VEGF versus FA implant during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting, and how the topics from his talk may be applied day to day in retinal practice.
See more ASRS meeting coverage here

Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

ASRS 2020: Diabetic retinopathy progression in anti-VEGF versus FA implant

Related Content

CTS 2026: OTX-TKI demonstrates superiority over aflibercept in wet AMD—what the SOL-1 data mean for retina practice

Ranluspec FDA approval: Cyrus Karkaria, PhD, on biosimilar access, prefilled syringes, and long-term switching confidence

Geographic atrophy: When lesion borders cannot be graded

Phase 3 NORTHSTAR trial launches for gildeuretinol in stargardt disease

The Retina TL;DR with Dr. Weng: Clinical trials, career, and community with David A. Eichenbaum, MD, FASRS

Latest CME

(CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

(COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop

(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Retina Updates in Montréal

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

Interventional Dry Eye: A Stepwise Treatment & Management Approach

Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Trending on Modern Retina

Ranluspec FDA approval: Cyrus Karkaria, PhD, on biosimilar access, prefilled syringes, and long-term switching confidence

CTS 2026: OTX-TKI demonstrates superiority over aflibercept in wet AMD—what the SOL-1 data mean for retina practice

Geographic atrophy: When lesion borders cannot be graded

The Retina TL;DR with Dr. Weng: Clinical trials, career, and community with David A. Eichenbaum, MD, FASRS

FDA guidance to help accelerate cell and gene therapies